ProPhase Labs, Inc. (PRPH) News
Filter PRPH News Items
PRPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PRPH News From Around the Web
Below are the latest news stories about PROPHASE LABS INC that investors may wish to consider to help them evaluate PRPH as an investment opportunity.
ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting MeasuresThe Company will review on Thursday, December 12th, at 12:00 p.m. EST. GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today provided updates on several key initiatives. Securing Low-Interest Rate Financing from a Global Private Equity Fund ProPhase has secured an agreement with a billion-dollar global private equity fund, providing flexible, low-interest rate debt f |
Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic VisionHOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company’s future. Dear Impact Biomedic |
ProPhase Labs Inc (PRPH) Q3 2024 Earnings Call Highlights: Strategic Launches and Financial ...ProPhase Labs Inc (PRPH) outlines aggressive product launches and cost-cutting measures while addressing significant accounts receivable issues. |
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on ProPhase’s business model, services offered, industry outlook, financial results, management commentary, valuation, and risks. The update note is available below. ProPhase Labs November 2024 Update Note Highlights from the note include: Launch |
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue EstimatesProPhase Labs (PRPH) delivered earnings and revenue surprises of -12.90% and 11.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses Company to hold a virtual conference call Wednesday, November 13, 2024, at 11:00 AM ET GARDEN CITY, NY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for th |
ProPhase Labs Announces Closing of Public Offering of Common StockGARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the closing of its previously announced underwritten public offering of 4,795,500 shares of its common stock, including 625,500 shares sold upon full exercise of the underwriter's option to purchase additional shares. Each share of common stock was sold at a public offering price of $0.72 per share, for g |
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, |
Top Midday DeclinersTop Midday Decliners |
ProPhase Labs Announces Pricing of Public Offering of Common StockGARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are |